Rheon Medical SA announced in January 2023, the formation of its new scientific advisory board (SAB); an international line-up of glaucoma experts who help advance the company’s clinical program. The management team has ambitious goals to continue their expansion in Europe and the Middle East, with parallel FDA clinical trials in the US. With this backdrop of extensive knowledge and clinical expertise, the SAB’s advisory role is a valuable asset to development.
For the full announcement see here.
